View : 165 Download: 0
Inhibition of hepatitis C virus in mouse models by lipidoid nanoparticle-mediated systemic delivery of siRNA against PRK2
- Inhibition of hepatitis C virus in mouse models by lipidoid nanoparticle-mediated systemic delivery of siRNA against PRK2
- Moon, Jae-Su; Lee, Seung-Hoon; Han, Song-Hee; Kim, Eun-Jung; Cho, Hee; Lee, Wooseong; Kim, Mi-Kyung; Kim, Tae-Eun; Park, Hyun-Ji; Rhee, Jin-Kyu; Kim, Seong-Jun; Cho, Seung-Woo; Han, Seung Hyun; Oh, Jong-Won
- Ewha Authors
- SCOPUS Author ID
- Issue Date
- Journal Title
- NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
- NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE vol. 12, no. 6, pp. 1489 - 1498
- HCV; siRNA; Lipidoid; Nanoparticles; PRK2; Antivirals
- ELSEVIER SCIENCE BV
- SCIE; SCOPUS
- Document Type
- Host-targeting antivirals have an advantage over direct-acting antivirals in that they have a high genetic barrier to resistance. Here, we describe in vivo anti-hepatitis C virus (HCV) efficacy of a potent siRNA targeting the protein kinase C-related kinase 2 (PRK2), which phosphorylates HCV NS5B RNA-dependent RNA polymerase and promotes HCV replication. PRK2-silencing reduced the phosphorylated NS5B level and resulted in inhibition of NS5B RdRp activity to decrease HCV genome abundance. Systemic administration of lipidoid nanoparticle-formulated PRK2 siRNA (once every three days for a total of three injections at a dose of 3 mg kg(-1)) resulted in a 3.72 and 1.96 log(10) reduction in serum HCV RNA titer, in mouse subcutaneous and orthotopic xenograft models for HCV replication, respectively. Our results verify the essential role of PRK2 in HCV replication and offer a host-targeting anti-HCV siRNA therapy that might be beneficial for non-responders to current treatment regimens. (C) 2016 Elsevier Inc. All rights reserved.
- Appears in Collections:
- 엘텍공과대학 > 식품공학전공 > Journal papers
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.